Sign in

You're signed outSign in or to get full access.

OI

Orgenesis Inc. (ORGS)·Q4 2020 Earnings Summary

Executive Summary

  • Orgenesis reported FY 2020 revenues of $7.65M (+96% y/y) and guided to “more than double” revenue in 2021 based on contracts already in hand; Q4 revenue (derived) accelerated to ~$2.30M vs ~$1.12M in Q4 2019, driven by point‑of‑care (POCare) services ramp and Koligo integration .
  • Operating investment intensified in Q4 to scale OMPUL (mobile processing) deployments and therapy validations; FY R&D was $84.0M and SG&A $19.0M, with Q4 accounting for a disproportionate share as programs moved toward clinical utility .
  • Management highlighted ~$38M of signed master agreements for 2021–2022 services, YE cash of ~$44.9M, no long‑term debt, and an aim to reach breakeven in 2021 if contracted revenues realize as expected .
  • Key narrative catalysts: OMPUL validations and hospital deployments, KYSLECEL automation/expansion, and regulatory progress across a 14‑country POCare network; these are the drivers behind the 2021 revenue doubling guide and potential stock reaction .

What Went Well and What Went Wrong

  • What Went Well

    • Revenue inflection: “revenues nearly doubled in 2020 to $7.7 million,” with management expecting “revenue to more than double in 2021 based on just the existing contracts in hand” .
    • Commercial pipeline and backlog: CFO cited “master agreements with partners in the aggregate amount of over $38 million for services to be provided from 2021 to 2022” .
    • Platform progress: Management unveiled OMPULs, citing advantages (short setup, lower cost, automation, modular scalability) and active validations, with partners now in 14 countries and 10 JVs to localize regulatory execution .

  • What Went Wrong

    • Heavy Q4 investment and losses: FY operating loss was $95.8M, with Q4 shouldering a large share as OMPUL validations and therapy adaptations accelerated (FY R&D $84.0M; FY SG&A $19.0M) .
    • Limited near‑term product revenue: KYSLECEL contributed only “minor revenue” in Q4; management indicated revenue lift is contingent on completing automation and deployment in the next ~6 months .
    • Consensus visibility limited: We were unable to retrieve S&P Global consensus EPS and revenue for Q4 (data access limit), and historical coverage appears sparse for this micro‑cap, reducing external estimate benchmarks (see Estimates Context).

Financial Results

Revenue and profitability vs prior quarters (USD):

MetricQ2 2020Q3 2020Q4 2020
Total Revenues ($M)$1.75 $1.73 $2.30 (FY $7.652 − 9M $5.356)
Operating Loss ($M)$(26.77) $(9.35) $(52.93) (FY $95.781 − 9M $42.851)
Net Loss from Continuing Ops ($M)$(27.12) $(9.57) $(77.49) (FY $95.127 − 9M $17.638)
Net EPS (Basic & Diluted, total)$(0.95) $(0.11) N/A (quarterly EPS not disclosed)

Revenue breakdown (where disclosed):

Revenue StreamQ2 2020Q3 2020Q4 2020
Cell Process Development Services ($M)$0.58 $0.46 N/A
Point‑of‑Care Services ($M)$1.17 $1.27 N/A
Total ($M)$1.75 $1.73 $2.30 (derived)

Select operating expense detail:

MetricQ2 2020Q3 2020Q4 2020
R&D Expense ($M)$24.72 $6.95 $47.20 (FY $83.99 − 9M $36.79)
SG&A Expense ($M)$3.61 $4.04 $7.80 (FY $18.97 − 9M $11.17)

Additional KPIs and balance sheet items:

KPIQ2 2020Q3 2020Q4 2020
Cash & Cash Equivalents ($M)$97.49 $88.76 $44.92
Signed Master Agreements (Services, 2021–2022)——~$38M
Countries with POCare Partners——14
Employees (approx.)——110–111

Notes: Q4 figures marked “derived” are calculated from FY 2020 minus 9M 2020 reported amounts.

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueFY 2021N/A“More than double” FY 2020 revenue based on contracts already in hand Raised/new
Services Master Agreements2021–2022N/A~$38M aggregate signed New disclosure
Breakeven TargetFY 2021N/AAim to be breakeven in 2021 if contracted revenues realize New target
KYSLECEL ContributionNext ~6 monthsN/AExpect “major change in revenue” post automation/OMPUL deployment New qualitative outlook

Earnings Call Themes & Trends

TopicPrevious Mentions (Q‑2 and Q‑1)Current Period (Q4 call)Trend
OMPULs (mobile units)Development underway; platform strategy outlined; COVID impact “minor” Unveiled OMPULs; validation progress; regulatory acceptance expected; deployment with hospital partners Acceleration to deployment
Commercial pipeline/backlogMasthercell sale strengthened liquidity; POCare services growing ~$38M master agreements for 2021–2022; 2021 revenue >2× 2020 Backlog materializing
KYSLECEL (Koligo)Koligo deal closed Oct 15, 2020 (post‑Q3) Minor Q4 revenue; expect step‑up after automation within ~6 months Near‑term build
Regulatory/validationCOVID “minor” business impact; regulatory support via partners Regulators supportive; validate at select centers before scale‑out Constructive
Liquidity/capitalCash $97.5M (Q2); $88.8M (Q3) YE cash ~$44.9M; no long‑term debt; well‑funded; optional at‑the‑market program Invest to scale

Management Commentary

  • “I am pleased to report that our revenues nearly doubled in 2020 to $7.7 million… Based on just the existing contracts in hand, we anticipate for revenue to more than double in 2021.” — Vered Caplan, CEO .
  • “These mobile systems [OMPULs] can be deployed onsite at a hospital… short set up time, small footprint, lower costs, automated operation, modular format, and highly scalable design.” — Vered Caplan .
  • “We have partnerships with leading hospitals and research centres in 14 countries… and have established 10 joint venture agreements…” — Vered Caplan .
  • “We have already signed master agreements… over $38 million for services to be provided from 2021 to 2022… We ended [2020] with cash and cash equivalents of approximately $44.9 million and have no long‑term debt.” — Neil Reithinger, CFO .

Q&A Highlights

  • OMPUL deployment and focus: First deployments will be disclosed with hospital approvals; initial focus on immuno‑oncology with adaptable use for pediatric/diabetes programs .
  • KYSLECEL revenue path: “Minor revenue” in Q4; major revenue change expected after automation and broader center deployment within ~6 months .
  • Unit economics: Targeting capacity of ~70–100 patients per OMPUL annually; price aspiration ~$100k per patient with gross profit comparable to historical CDMO (~50%), and scalable via additional units at validated sites .
  • U.S. regulatory posture: Expect validation at a few centers first; regulators seen as supportive given standardized, automated processes vs manual clean‑room variability .
  • Hiring and resources: ~110–111 employees at year‑end; recent hires across process engineering, quality systems, and clinical operations to support scaling .

Estimates Context

  • Consensus EPS and revenue for Q4 2020 were not retrieved due to S&P Global data access limits, and external coverage appears limited for ORGS at that time. As a result, we benchmark results versus prior quarters and management’s guidance/backlog disclosures rather than consensus comparisons (SPGI daily limit reached during retrieval attempt).

Key Takeaways for Investors

  • The 2020 exit rate improved: derived Q4 revenue of ~$2.30M vs $1.12M in Q4 2019 (+105% y/y) indicates sequential acceleration into 2021 alongside ~$38M of contracted services .
  • 2021 revenue doubling guide is anchored by specific signed MSAs and near‑term catalysts (OMPUL validations, KYSLECEL automation), not solely pipeline optionality .
  • Heavy Q4 spend was strategic (validations, automation, regional regulatory execution) and front‑loaded; management targets breakeven in 2021 if contracted revenue realizes, with YE cash of ~$44.9M and no long‑term debt providing runway .
  • The OMPUL/POCare model is the core differentiator: distributed, automated production is intended to compress costs and timelines, expanding therapy access and enabling scale—watch for validation milestones and first multi‑center deployments .
  • KYSLECEL is a near‑term proof point: automation and expanded center footprint could materially lift product revenue within ~6 months from the call, providing an early case study for the platform’s commercial leverage .
  • Execution risks remain: regulatory validation by geography, hospital adoption pace, and timely conversion of MSAs to revenue are critical; quarterly variability likely as deployments scale .
  • Trading setup: Upcoming OMPUL deployment disclosures, KYSLECEL automation updates, and quarterly revenue cadence versus “>2x” 2021 guide are the primary stock catalysts near term .

Source Documents

  • FY2020 Press Release/8‑K (includes financial statements): .
  • Q4 2020 Earnings Call Transcript: .
  • Q3 2020 10‑Q: .
  • Q2 2020 10‑Q: .